Tandem Diabetes (NASDAQ: TNDM) reported Q4 EPS of $0.02, $0.22 better than the analyst estimate of ($0.20). Revenue for the quarter came in at $76.2 million versus the consensus estimate of $56.34 million.

“2018 was both extraordinary and transformative for our Company, as we entered the year fighting for a place in the domestic insulin pump market and exited as a global leader in diabetes technology,” said Kim Blickenstaff, president and chief executive officer. “All of the same catalysts that drove our growth in 2018 are still in place: our differentiated pump platform, automated insulin delivery algorithms, international expansion and the underlying passion of our employees to improve the lives of people with diabetes. Together, they present us with a tremendous opportunity for the year ahead.”

“Steady improvement in both operating and gross margins throughout 2018 resulted in our substantial reduction of cash use, which combined with our elimination of debt, allowed us to reach the milestone of generating cash in the fourth quarter ahead of our expectations,” said Leigh Vosseller, executive vice president and chief financial officer. “These accomplishments further reinforce our confidence in attaining our long-term profitability goals.”

GUIDANCE:

Tandem Diabetes sees FY2019 revenue of $255-270 million, versus the consensus of $219.48 million.

For earnings history and earnings-related data on Tandem Diabetes (TNDM) click here.